Literature DB >> 16641467

Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.

Blair Capitano1, Brian A Potoski, Shahid Husain, Shimin Zhang, David L Paterson, Sean M Studer, Kenneth R McCurry, Raman Venkataramanan.   

Abstract

Voriconazole penetrated well into the pulmonary epithelial lining fluid (ELF) in lung transplant patients receiving oral prophylaxis. The ELF concentrations exceeded those of the plasma, with an average ELF-to-plasma ratio of 11 (+/-8). A strong association between plasma and ELF concentrations (r(2) = 0.95) was noted.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16641467      PMCID： PMC1472209          DOI： 10.1128/AAC.50.5.1878-1880.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry.

Authors:  Lei Zhou; Randolph D Glickman; Nancy Chen; William E Sponsel; John R Graybill; Kwok-Wai Lam
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-09-05       Impact factor: 3.205

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.

Authors:  S Trifilio; R Ortiz; G Pennick; A Verma; J Pi; V Stosor; T Zembower; J Mehta
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

4.  Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors:  T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

5.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

7.  Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

Authors:  Blair Capitano; Holly M Mattoes; Eric Shore; Aidan O'Brien; Sidney Braman; Chistina Sutherland; David P Nicolau
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

8.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Authors:  S J Roffey; S Cole; P Comby; D Gibson; S G Jezequel; A N R Nedderman; D A Smith; D K Walker; N Wood
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

9.  Phagocytosis and intracellular fate of Aspergillus fumigatus conidia in alveolar macrophages.

Authors:  O Ibrahim-Granet; B Philippe; H Boleti; E Boisvieux-Ulrich; D Grenet; M Stern; J P Latgé
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

10.  In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

Authors:  Peter A Warn; Andrew Sharp; David W Denning
Journal:  J Antimicrob Chemother       Date:  2005-11-10       Impact factor: 5.758
View more
  23 in total

1.  Human tissue distribution of voriconazole.

Authors:  Stefan Weiler; David Fiegl; Róisín MacFarland; Eva Stienecke; Rosa Bellmann-Weiler; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.

Authors:  Siow-Chin Heng; Gregory I Snell; Bronwyn Levvey; Dominic Keating; Glen P Westall; Trevor J Williams; Helen Whitford; Roger L Nation; Monica A Slavin; Orla Morrissey; David C M Kong
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 4.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

Review 5.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

Authors:  Keith A Rodvold; Liz Yoo; Jomy M George
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

6.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

7.  Aerosolized Delivery of Antifungal Agents.

Authors:  Jennifer Le; Daryl S Schiller
Journal:  Curr Fungal Infect Rep       Date:  2010-04-13

Review 8.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.

Authors:  Stefan Weiler; Gerda Falkensammer; Angelika Hammerer-Lercher; Markus Anliker; Helene Vogelsinger; Michael Joannidis; Stefan Dunzendorfer; Markus Stein; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

10.  Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.

Authors:  John E Conte; Jeffrey A Golden; Gopal Krishna; Marina McIver; Emily Little; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.